Sentence examples for mg group but from inspiring English sources
Renal dysfunction, hypotension, and hyperkalemia were more common in the 150 mg than in the 50 mg group, but the discontinuation rates were similar in both groups.
Monitoring for immunoreactivity during the first treatment year of ANCHOR revealed an increase from baseline in the number of patients testing positive in the 0.5 mg group but not the 0.3 mg or verteporfin groups at 12 months.
In the unmyelinated neurons, greater reduction of TRPA1 IR cells was observed in the BV 0.1 mg group compared with the BV 0.05 mg group, but a similar dose relationship was not observed in myelinated neurons.
At 12 months, mean change in VA increased by 8.5 letters in the ranibizumab 0.3 mg group and by 11.3 letters in the 0.5 mg group, but decreased by 9.5 letters in the sham group (P<0.0001).
Diarrhea was reported most frequently in the azilsartan medoxomil 40mg+amlodipinee 5 mg group, but no cases were observed in the azilsartan medoxomil 80mg+amlodipinee 5 mg group.
The entire defect area was covered with mineralized bone tissue at 8 weeks in the CMC/BioC/BMP-2 (0.5 mg) group but not in the CMC/BioC or CMC/BioC/BMP-2 (0.1 mg) group.
The infiltration of neutrophils was not observed in the EAE without injection, EAE with hIgGcont, hIgGNMO, and E5415A (0.01 mg) groups, but was present in the E5415A-injected groups (0.1 1 mg), i.e. in 52 of 84 spinal cord axial sections (62 %) in five rats in the 0.1 mg group and 83 out of 83 sections (100%%) in five rats in the 1 mg group.
Similar responses were observed in the 200-mg group, but these did not reach significance, possibly because of the smaller size of the subgroups.
Two fractures did occur in the dapagliflozin 5-mg group, but all patients received pioglitazone, and thiazolidinediones are known to increase the risk of fractures (19).
There were no observable improvements in the 210-mg group over the 140-mg group, but the improvements in the 280-mg group were nominally higher than those of the other brodalumab treatment groups (Table 3; Figs 1 and 2).
In addition to rapid blockade of the IL-17 pathway, ixekizumab significantly suppressed 765 disease-related genes in week 2 biopsy specimens in the 150-mg group but not the placebo group.
